Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.41 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328906 | 0.93 | SCN9A (0.47) | SCN9AKDM4EALDH1A1GLAGAA | |
| SCHEMBL6330986 | 0.78 | ALDH1A1 (0.73) | SCN9AKDM4EALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL6336714 | 0.77 | KDM4E (0.71) | SCN9AKDM4EALDH1A1GLAGAA | |
| SCHEMBL5788700 | 0.76 | TRIM58 (0.45) | NTRK1 | |
| SCHEMBL5785783 | 0.76 | ADORA2A (0.45) | SCN9AGLAADORA2AADORA1ACHE | |
| SCHEMBL4179234 | 0.75 | MAPK14 (0.48) | GLAADORA2AADORA1FERMT2BCDIN3D | |
| SCHEMBL5787957 | 0.74 | ADORA2A (0.48) | KDM4EALDH1A1GLAADORA2AADORA1 | |
| SCHEMBL6329201 | 0.74 | GAA (0.46) | SCN9AKDM4EALDH1A1GLAGAA | |
| SCHEMBL5785239 | 0.73 | CHEK2 (0.47) | SCN9AALDH1A1APPACHEMAPK14 | |
| SCHEMBL4179781 | 0.73 | MAPK14 (0.58) | FERMT2BCDIN3DMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | claimed |
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | SCN9A 801/4885KDM4E 1392/4885ALDH1A1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.